Biomea Fusion (BMEA) Projected to Post Quarterly Earnings on Wednesday

Biomea Fusion (NASDAQ:BMEA - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of ($0.64) per share for the quarter.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.04. On average, analysts expect Biomea Fusion to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Biomea Fusion Price Performance

BMEA stock opened at $1.82 on Wednesday. Biomea Fusion has a 1-year low of $1.29 and a 1-year high of $13.07. The business has a fifty day moving average price of $1.89 and a 200-day moving average price of $2.56. The stock has a market capitalization of $68.38 million, a P/E ratio of -0.51 and a beta of -0.13.

Wall Street Analyst Weigh In

Several analysts have issued reports on BMEA shares. Citigroup cut their price target on Biomea Fusion from $22.00 to $9.00 and set a "buy" rating for the company in a report on Wednesday, July 16th. Piper Sandler started coverage on Biomea Fusion in a research note on Tuesday, June 3rd. They issued an "overweight" rating and a $7.00 price objective for the company. HC Wainwright dropped their price objective on Biomea Fusion from $40.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. D. Boral Capital reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Biomea Fusion in a research note on Monday. Finally, Barclays dropped their price target on Biomea Fusion from $11.00 to $3.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 2nd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Biomea Fusion currently has an average rating of "Buy" and a consensus price target of $20.10.

Hedge Funds Weigh In On Biomea Fusion

An institutional investor recently raised its position in Biomea Fusion stock. AQR Capital Management LLC raised its position in Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) by 670.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 264,028 shares of the company's stock after buying an additional 229,763 shares during the period. AQR Capital Management LLC owned about 0.70% of Biomea Fusion worth $562,000 at the end of the most recent reporting period. 96.72% of the stock is currently owned by institutional investors.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.